Olive

Olive was founded in 2012 by Sean Lane, initially operating under different business models before pivoting to focus on selling automation software, marketed heavily as artificial intelligence, that hospitals and health systems could use to automate repetitive administrative tasks in revenue cycle management, such as verifying patient insurance eligibility, processing prior authorization requests, and managing claims, work that traditionally requires substantial manual administrative staff time at hospitals and physician practices. Olive experienced an extraordinarily rapid rise during the COVID-19 pandemic and the broader 2020-2021 digital health funding boom, raising $225 million at a $1.5 billion valuation in December 2020, then $400 million just seven months later at a reported $4 billion valuation, becoming the highest-valued healthcare AI startup at the time, with the company claiming its technology was deployed at more than 900 hospitals across over 40 U.S. states. The company's rapid ascent, however, proved unsustainable: Olive had grown very quickly partly through an aggressive acquisition strategy, purchasing companies including Verata Health and Empiric Health to expand its product offerings faster than organic development would have allowed, but subsequent reporting, including a widely cited 2023 Axios investigation, raised questions about how much of Olive's advertised "AI" automation actually relied on manual human labor behind the scenes to handle exceptions and complex cases that its automated systems could not reliably process independently, undercutting the company's core value proposition. Facing mounting financial pressure as the broader digital health funding environment cooled sharply from its 2021 peak, Olive laid off 450 employees in July 2022 and an additional 200 in February 2023, before ultimately announcing in October 2023 that it would sell its two core business units, its clearinghouse and patient access technology to Waystar, and its prior authorization technology to Humata Health (a company led by former Olive executives), and wind down all remaining operations, an outcome that used an out-of-court asset sale process rather than formal bankruptcy but nonetheless represented a near-total loss for investors who had funded the company at its $4 billion peak valuation, becoming a widely cited cautionary example of the broader 2021-era digital health and AI hype cycle correction.

News

No news available for this company.